Fangzhou’s ‘XingShi’ LLM Gains Recognition from Nature News and Xinhua for its AI Innovation in Chronic Disease Care

SHANGHAI, Sept. 26, 2025 – Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a prominent provider of AI-powered Internet healthcare solutions, has announced that its “XingShi” Large Language Model (“XS LLM”) gained prominence in a Nature News article titled “A Chinese AI tool can manage chronic disease — could it revolutionize health care?”

Authored by science reporter Mohana Basu, the feature highlighted the model’s prospective uses in chronic disease management, alongside insights from expert commentators. Xinhua News Agency further drew attention to the article with its headline, “Nature focuses on Fangzhou’s XS LLM: Chinese AI tackling global chronic disease challenges.”

This acknowledgment emphasizes AI’s increasingly significant role in tackling global health concerns. Fangzhou’s XS LLM, launched in September, was specifically developed to confront existing healthcare difficulties like inefficient chronic disease management, simultaneously facilitating enhanced service personalization and optimizing physicians’ often-limited schedules.

“The recognition from Nature underscores that Chinese innovation in AI-powered healthcare is attracting global notice,” stated Dr. Xie Fangmin, Fangzhou’s Founder, Chairman, and CEO. “Through the XS LLM, our objective is to deliver a scalable, dependable, and patient-focused solution capable of not only revolutionizing chronic disease management within China but also providing valuable perspectives for healthcare globally.”

The XS LLM incorporates multimodal functionalities—including image and speech recognition, natural language processing, extensive medical knowledge storage, and reasoning—while concurrently setting advanced performance standards in medical AI. This foundational system supports five specialized intelligent agents: the “AI Knowledge Agent,” “AI Guidance Agent,” “AI Pre-Consult Agent,” “AI Doctor Assistant,” and “AI-Electronic Medical Record (EMR) Agent.” Collectively, these agents establish a comprehensive, closed-loop service framework that covers the entire spectrum of chronic disease management.

Conceived as the “core digital brain” of Fangzhou’s platform, the model currently drives five AI-driven applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each of these products caters to specific clinical and patient-centric use cases, facilitating real-time, precise interventions spanning medication advice, patient instruction, diagnostic support, and medical information retrieval.

The Nature news feature highlighted Fangzhou’s XS LLM as a groundbreaking instrument for chronic disease management, underscoring its seamless integration of image, speech, and language proficiencies combined with medical reasoning to enhance personalized patient care. The report noted that the platform presently serves more than 50 million registered users and over 200,000 physicians, thereby establishing it as a prime illustration of China’s AI innovation making its mark on the international healthcare arena.

Fangzhou has also proactively mitigated the risks associated with “AI hallucination” through refined data tuning, model optimization, augmented supervision, and improved regulatory compliance. The Company has affirmed its commitment to advancing its AI research and broadening applications within chronic disease care, thereby further contributing to the “Healthy China 2030” initiative.

About Fangzhou Inc.
Fangzhou Inc. (06086.HK) stands as China’s foremost online platform for chronic disease management, catering to 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company excels in providing customized medical care and AI-powered precision medicine solutions. For additional details, please visit .

Media Contact
For further questions or interview requests, kindly contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release includes forward-looking statements. Actual outcomes may vary significantly from those projected owing to a range of factors. Readers are advised against placing excessive reliance on these statements.